CD86 and glioblastoma: Immunophenotyping analysis of DCs showed that the activity of DCs in GBM patients was much lower than that in GII–III patients and even lower than that in healthy subjects without tumor antigen stimulation; GBM DCs exhibited decreased expression of antigen-recognized HLA-A (Fig. 1j), the costimulatory molecules CD40 and CD86 (Fig. 1k, l) and the antigen-processing protein TAP1 (Fig. 1m).